Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials THORAX Saketkoo, L. A., Mittoo, S., Huscher, D., Khanna, D., Dellaripa, P. F., Distler, O., Flaherty, K. R., Frankel, S., Oddis, C. V., Denton, C. P., Fischer, A., Kowal-Bielecka, O. M., LeSage, D., Merkel, P. A., Phillips, K., Pittrow, D., Swigris, J., Antoniou, K., Baughman, R. P., Castelino, F. V., Christmann, R. B., Christopher-Stine, L., Collard, H. R., Cottin, V., Danoff, S., Highland, K. B., Hummers, L., Shah, A. A., Kim, D. S., Lynch, D. A., Miller, F. W., Proudman, S. M., Richeldi, L., Ryu, J. H., Sandorfi, N., Sarver, C., Wells, A. U., Strand, V., Matteson, E. L., Brown, K. K., Seibold, J. R. 2014; 69 (5): 428-436

Abstract

Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack of consensus on appropriate outcome measures for reliably assessing treatment response. In the setting of connective tissue diseases (CTDs), some measures of ILD disease activity and severity may be confounded by non-pulmonary comorbidities.The Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) working group of Outcome Measures in Rheumatology-a non-profit international organisation dedicated to consensus methodology in identification of outcome measures-conducted a series of investigations which included a Delphi process including >248 ILD medical experts as well as patient focus groups culminating in a nominal group panel of ILD experts and patients. The goal was to define and develop a consensus on the status of outcome measure candidates for use in randomised controlled trials in CTD-ILD and idiopathic pulmonary fibrosis (IPF).A core set comprising specific measures in the domains of lung physiology, lung imaging, survival, dyspnoea, cough and health-related quality of life is proposed as appropriate for consideration for use in a hypothetical 1-year multicentre clinical trial for either CTD-ILD or IPF. As many widely used instruments were found to lack full validation, an agenda for future research is proposed.Identification of consensus preliminary domains and instruments to measure them was attained and is a major advance anticipated to facilitate multicentre RCTs in the field.

View details for DOI 10.1136/thoraxjnl-2013-204202

View details for Web of Science ID 000347648600009

View details for PubMedID 24368713

View details for PubMedCentralID PMC3995282